OTCMKTS:LOGC LogicBio Therapeutics Q3 2026 Earnings Results & Report $15.03 -0.12 (-0.79%) As of 10:56 AM Eastern LogicBio Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 9, 2026. The company reported EPS of -$0.29 versus the -$0.0419 consensus estimate. Research:ProfileEarnings History Earnings Announcement Details QuarterQ3 2026Report DateNovember 9, 2026TimeAfter Market ClosesConference Call8:30 AM ET LogicBio Therapeutics EPS ResultsActual EPS-$0.29Consensus EPS -$0.0419Beat/MissMissed by -$0.2481One Year Ago EPSN/AEPS Beat Rate4 of last 6 quartersLogicBio Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$23.31 millionBeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) LogicBio Therapeutics Q3 2026 Earnings FAQ Did LogicBio Therapeutics beat earnings estimates for Q3 2026? LogicBio Therapeutics (OTCMKTS:LOGC) reported earnings of -$0.29 per share for Q3 2026, missing the consensus estimate of -$0.0419. The report was announced on Monday, November 9, 2026. LogicBio Therapeutics Earnings HeadlinesContextLogic Holdings Inc. Reports Third-Quarter 2026 Financial Results3 hours ago | globenewswire.comLogicBio Therapeutics (LOGC) Set to Announce Earnings on TuesdayNovember 2, 2026 | americanbankingnews.comUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 9 at 1:00 AM | Digest Publishing (Ad)ContextLogic Holdings Inc. Publishes Q&A Following Second Quarter 2026 ResultsAugust 21, 2026 | globenewswire.comContextLogic Holdings Inc. Reports Second-Quarter 2026 Financial ResultsAugust 13, 2026 | globenewswire.comContextLogic to Acquire gChem for $850 MillionAugust 5, 2026 | globenewswire.comSee More LogicBio Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like LogicBio Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LogicBio Therapeutics and other key companies, straight to your email. Email Address About LogicBio TherapeuticsLogicBio Therapeutics (OTCMKTS:LOGC) was a clinical-stage genetic medicine company focused on developing therapies for patients with serious genetic and metabolic diseases. The company’s research centered on genetic medicine technologies designed to address the underlying causes of disease rather than treat symptoms alone. LogicBio’s principal platform, GeneRide, was developed to enable the targeted insertion of therapeutic genes into the genome. The company also pursued GeneWare, a platform intended to support gene-editing applications. Its development programs included LB-001, an investigational treatment for methylmalonic acidemia, and additional programs targeting genetic disorders such as hemophilia. Founded in 2014 and headquartered in Lexington, Massachusetts, LogicBio operated as a biotechnology company serving the global genetic medicine market through research and clinical development activities. Fred Chereau served as the company’s president and chief executive officer during its publicly traded period. In 2022, Alexion, AstraZeneca’s rare-disease business, completed its acquisition of LogicBio. Following the transaction, LogicBio became a wholly owned subsidiary, and its standalone public-company operations and stock listing were discontinued.View LogicBio Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 11/2 - 11/6IonQ's Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?Atlassian Tanks After Huge Run as Guidance Disappoints, But Strength RemainsThe Ugly Truth Behind SoundHound’s Q3 ResultsSandisk Shares Are Oversold: Bargain or Value Trap?Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?CVS Raised Its Outlook and Announced a Breakup—So Why Did the Stock Drop? Upcoming Earnings Petroleo Brasileiro S.A.- Petrobras (11/10/2026)Transdigm Group (11/10/2026)Honda Motor (11/11/2026)Franco-Nevada (11/11/2026)Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
